- Home
- URGN vs RLX Comparison
URGN vs RLX Comparison
Compare URGN & RLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | RLX |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | URGN | RLX |
|---|---|---|
| Price | $34.58 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $60.00 | $2.77 |
| AVG Volume (30 Days) | 794.9K | ★ 1.2M |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | ★ 6.71% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $193.48 | $62.88 |
| Revenue Next Year | $64.99 | $23.93 |
| P/E Ratio | ★ N/A | $28.09 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.50 | $1.64 |
| 52 Week High | $50.81 | $2.60 |
Technical Indicators
Market Signals| Indicator | URGN | RLX |
|---|---|---|
| Relative Strength Index (RSI) | 31.30 | 28.11 |
| Support Level | $34.18 | N/A |
| Resistance Level | $44.27 | $1.75 |
| Average True Range (ATR) | 2.17 | 0.04 |
| MACD | -0.24 | -0.00 |
| Stochastic Oscillator | 10.65 | 10.71 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
About RLX RLX Technology Inc. each representing the right to receive one (1) ordinary share
RLX Technology Inc is engaged in the manufacturing of e-vapor products for adult smokers. It has an integrated offline distribution and "Branded store plus" retail model tailored to China's e-vapor market. The company has two reportable segments, Core Markets and Europe Acquisition. The majority of the revenue is earn from Core Markets segment.